Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reiss

Showing results (261-270 of 509) with videos related to

Pageof 51
Sort By:
AIDS (London, England)|December 15, 2010
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsElsayed Z Soliman, Jens D Lundgren, Mollie P Roediger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2008
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA StudyWendy P Bannister, Alessandro Cozzi-Lepri, Bonaventura Clotet, et al.
Antiviral Therapy|March 27, 2009
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyMatthijs van Luin, Wendy P Bannister, Amanda Mocroft, et al.
AIDS (London, England)|May 9, 2009
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavirMarit G A van Vonderen, Paul Lips, Michiel A van Agtmael, et al.
Plos One|November 4, 2014
Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective studyPhilippe R Mutwa, Kimberly R Boer, Brenda Asiimwe-Kateera, et al.
AIDS Research and Treatment|August 11, 2015
Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 MonthsBrenda Asiimwe-Kateera, Nienke Veldhuijzen, Jean Paul Balinda, et al.
AIDS (London, England)|June 3, 2009
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapyAnouk M Kesselring, Ferdinand W Wit, Caroline A Sabin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 5, 2005
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissueMarion A M den Boer, Jimmy F P Berbée, Peter Reiss, et al.
AIDS (London, England)|February 9, 2016
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?David C Boettiger, Caroline A Sabin, Andrew Grulich, et al.
Journal of Virus Eradication|March 14, 2022
The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative studyKim A G J Romijnders, Laura de Groot, Sigrid C J M Vervoort, et al.
Pageof 51

Showing results (261-270 of 509) with videos related to

Sort By:
Pageof 51
AIDS (London, England)|December 15, 2010
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsElsayed Z Soliman, Jens D Lundgren, Mollie P Roediger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2008
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA StudyWendy P Bannister, Alessandro Cozzi-Lepri, Bonaventura Clotet, et al.
Antiviral Therapy|March 27, 2009
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyMatthijs van Luin, Wendy P Bannister, Amanda Mocroft, et al.
AIDS (London, England)|May 9, 2009
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavirMarit G A van Vonderen, Paul Lips, Michiel A van Agtmael, et al.
Plos One|November 4, 2014
Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective studyPhilippe R Mutwa, Kimberly R Boer, Brenda Asiimwe-Kateera, et al.
AIDS Research and Treatment|August 11, 2015
Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 MonthsBrenda Asiimwe-Kateera, Nienke Veldhuijzen, Jean Paul Balinda, et al.
AIDS (London, England)|June 3, 2009
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapyAnouk M Kesselring, Ferdinand W Wit, Caroline A Sabin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 5, 2005
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissueMarion A M den Boer, Jimmy F P Berbée, Peter Reiss, et al.
AIDS (London, England)|February 9, 2016
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?David C Boettiger, Caroline A Sabin, Andrew Grulich, et al.
Journal of Virus Eradication|March 14, 2022
The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative studyKim A G J Romijnders, Laura de Groot, Sigrid C J M Vervoort, et al.
Pageof 51